Select a medication above to begin.
docetaxel
generic
Black Box Warnings .
Mortality
treatment-related mortality incr. w/ abnormal liver fxn, at higher doses, and in pts w/ NSCLC and prior platinum-based tx if given docetaxel 100 mg/m^2 as monotherapy
Hepatic Impairment
do not use if bilirubin >ULN or AST and/or ALT >1.5x ULN w/ alk phos >2.5x ULN; incr. risk for severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death; higher rate of febrile neutropenia w/ isolated AST or ALT >1.5x ULN; monitor bilirubin, AST/ALT, and alk phos prior to each cycle
Neutropenia
do not use if ANC <1500 cells/mm^3; severe neutropenia w/ infection may occur; monitor CBC frequently
Severe Hypersensitivity Rxn
may incl. generalized rash/erythema, hypotension, bronchospasm, very rarely fatal anaphylaxis; reported in pts receiving dexamethasone premed; immediately D/C infusion, admin. appropriate tx if hypersensitivity rxns occur; do not use if severe hypersensitivity rxn hx to docetaxel or other drugs formulated w/ polysorbate 80
Severe Fluid Retention
occurs in 6.5% of pts despite dexamethasone premed; may incl. one or more of the following: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, pronounced abdominal distension due to ascites
Adult Dosing .
Dosage forms: INJ
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments
breast CA
- [node-positive adjuvant tx]
- Dose: 75 mg/m^2/dose IV x1 on day 1 of 21-day cycle; Info: give x6 cycles; part of multi-drug chemo regimen
- [locally advanced or metastatic dz, monotherapy]
- Dose: 60-100 mg/m^2/dose IV x1 on day 1 of 21-day cycle
- [metastatic dz, combo w/ capecitabine (off-label)]
- Dose: 75 mg/m^2/dose IV x1 on day 1 of 21-day cycle; Info: for anthracycline-resistant dz
non-small cell lung CA, locally advanced or metastatic
- [75 mg/m^2/dose IV x1 on day 1 of 21-day cycle]
- Info: use w/ cisplatin for tx-naive pts or as monotherapy for platinum-resistant dz
prostate CA
- [metastatic castration-resistant dz]
- Dose: 75 mg/m^2/dose IV x1 on day 1 of 21-day cycle; Info: give up to 10 cycles; use w/ prednisone 5 mg PO bid
- [metastatic castration-sensitive dz (off-label)]
- Dose: 75 mg/m^2/dose IV x1 on day 1 of 21-day cycle; Start: w/in 6wk after starting darolutamide; Info: give x6 cycles; use w/ darolutamide; use w/ GnRH analog in pts w/o bilateral orchiectomy
- [metastatic castration-sensitive, high-volume dz (off-label)]
- Dose: 75 mg/m^2/dose IV x1 on day 1 of 21-day cycle; Info: for pts w/ de novo metastatic dz w/ at least 4 bone metastases or any visceral dz; give up to 6 cycles; use w/ abiraterone and steroid; use w/ GnRH analog in pts w/o bilateral orchiectomy
gastric CA, advanced
- [75 mg/m^2/dose IV x1 on day 1 of 21-day cycle]
- Info: part of multi-drug chemo regimen
squamous cell head/neck CA, locally advanced
- [75 mg/m^2/dose IV x1 on day 1 of 21-day cycle]
- Info: give x3-4 cycles; part of multi-drug chemo regimen
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin >ULN: avoid use; AST and/or ALT >1.5x ULN w/ alk phos >2.5x ULN: avoid use
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.